67Cu-SARTATE ™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma

Condition:   Neuroblastoma Interventions:   Drug: 67Cu-SARTATE;   Drug: 64Cu-SARTATE Sponsor:   Clarity Pharmaceuticals Ltd Not yet recruiting

Source: ClinicalTrials.gov - July 17, 2019 Category: Research Source Type: clinical trials